The company
Virax Biolabs Group Limited -
VRAX · Nasdaq
VRAX stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 59.2% below that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 52
- Industry in uptrend
- 48% -2 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 2 (-1)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.
Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
No open-market buy or sale by its insiders on record.
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| JANE STREET GROUP, LLCnew · filed 14 Aug 2026 | 26,385$78K | +26,385 |
| UBS Group AGnew · filed 13 Aug 2026 | 4$12 | +4 |
News
No headline names it lately.
Everyone who traded it
Nobody on record has traded it.
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.